NYSE:HIMSHealthcare
FDA Peptide Shift And Leadership Change Could Be A Game Changer For Hims & Hers Health (HIMS)
In July 2026, an FDA advisory committee recommended easing compounding restrictions on several peptides, including BPC-157, while Hims & Hers Health announced that long-serving Chief Accounting Officer and Principal Accounting Officer Irene Becklund will resign in October 2026 and remain on as an advisor during the transition.
The FDA panel’s stance directly affects Hims & Hers Health’s growing peptide operations, including its California compounding facility, potentially widening the range...